Group 1 - The company announced the early repayment of a loan to an affiliated party, which is a normal market transaction [3][4] - The loan amount was 100 million yuan with a term of 3 months and an interest rate of 5% [2] - The total interest paid during the loan period was 680,555.56 yuan [3] Group 2 - The early repayment is expected to lower the company's debt-to-asset ratio and reduce financing and financial costs [4] - The debt and guarantee relationship between the company’s subsidiary and the affiliated party has been terminated following the repayment [3]

Group 1 - The company has not distributed cash dividends or bonus shares during the reporting period [3] - The company plans to hold the 2025 third extraordinary general meeting on August 27, 2025 [12][49] - The board of directors and the supervisory board have approved the 2025 semi-annual report and its summary [9][16] Group 2 - The company will engage in additional daily related transactions with Tibet Zhongjin Xinlian Blasting Engineering Co., Ltd. amounting to 18 million yuan for 2025 [10][17] - The company will also have additional related transactions with its controlling shareholder's subsidiary, Tibet Tianhui Human Resource Management Development Co., Ltd., amounting to 25 million yuan for 2025 [11][34] - The total amount of related transactions with Tibet Jian Gong Jian Cai Group Co., Ltd. and related parties from January to June 2025 is 25,587,129.03 yuan [45]

Group 1 - The company held its 30th meeting of the 4th Board of Directors on August 11, 2025, to discuss a major asset restructuring and related transactions [1] - The board approved a proposal to acquire 49% of Nanjing Wanyou Commercial Management Co., Ltd. from Huainan Shengyu and Huainan Huixiang for a total consideration of 1,379.225 million yuan [2][3] - The acquisition will allow the company to control 75.01% of Nanjing Wanyou after the transaction [1] Group 2 - The net asset value of the acquired assets is expected to exceed 50% of the company's audited net assets from the last fiscal year, amounting to over 50 million yuan [2] - The board's decision was supported by independent directors and the strategic committee, with a voting outcome of 6 in favor, 0 against, and 2 abstentions [2][3] Group 3 - The transaction involves cash payment and does not affect the company's control [3] - The board also approved the signing of a conditional asset purchase agreement with the involved parties [8] Group 4 - The performance commitment period for the acquired company is set for the years 2025, 2026, and 2027, with minimum net profit targets established for each year [6] - The board confirmed that the transaction complies with relevant regulations and does not constitute a restructuring scenario as defined by the regulatory framework [12][13] Group 5 - The board has established measures to ensure the protection of minority investors' interests regarding potential dilution of immediate returns due to the transaction [17] - The company will not hold a shareholder meeting immediately but will announce a date for the meeting to discuss the transaction [20]

证券代码：300972 证券简称：万辰集团 公告编号：2025-059 福建万辰生物科技集团股份有限公司 一、监事会会议召开情况 福建万辰生物科技集团股份有限公司（以下简称"公司"或"上市公司"）第四 届监事会第三十次会议于 2025 年 8 月 11 日在公司会议室以现场结合通讯方式 召开，本次监事会会议通知于 2025 年 8 月 8 日以书面、电子邮件的形式向公司 全体监事发出。会议应参与表决监事 3 名，实际参与表决监事 3 名，会议由公司 监事会主席陈毅勇主持，公司董事会秘书列席会议。本次会议的召开符合《中华 人民共和国公司法》等相关法律、法规以及《福建万辰生物科技集团股份有限公 司章程》的规定。 二、监事会会议审议情况 全体与会监事经认真审议，形成以下决议： （一）审议通过《关于公司本次重大资产重组暨关联交易符合上市公司重大 资产重组条件的议案》 公司拟通过支付现金的方式向淮南市盛裕企业管理有限公司（以下简称"淮 南盛裕"）和淮南市会想企业管理有限公司（以下简称"淮南会想"）购买所持有的 南京万优商业管理有限公司（以下简称"南京万优"、"标的公司"）49%股权（以 下简称"本次交易"），交易对价为 ...

依据现行法律法规的要求，本次交易尚需获得公司股东会审议通过。基于 公司对本次交易相关工作的整体安排，董事会决定公司暂不召开股东会，待相 关程序履行完毕后公司将另行召开董事会，提请公司股东会审议本次交易相关 事项并发布召开公司股东会的通知。 特此公告。 证券代码：300972 证券简称：万辰集团 公告编号：2025-060 福建万辰生物科技集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 福建万辰生物科技集团股份有限公司（以下简称"公司"或"上市公司"） 拟通过支付现金的方式向淮南市盛裕企业管理有限公司（以下简称"淮南盛裕"） 和淮南市会想企业管理有限公司（以下简称"淮南会想"）购买所持有的南京万 优商业管理有限公司（以下简称"南京万优"、"交易标的"）49%股权（以下 简称"本次交易"），交易对价为 137,922.50 万元。 公司于 2025 年 8 月 11 日召开了第四届董事会第三十次会议及第四届监事 会第三十次会议，审议通过了《关于 <福建万辰生物科技集团股份有限公司重大> 资产购买暨关联交易报告书（草案）>及其摘要的议案》等与本次交 ...

福建万辰生物科技集团股份有限公司（以下简称"上市公司"或"公 司"）拟以支付现金的方式购买淮南市盛裕企业管理有限公司和淮南市会想 企业管理有限公司合计持有的南京万优商业管理有限公司49.00%股权（以下 简称"本次交易"）。根据《上市公司重大资产重组管理办法》相关规定， 本次交易构成重大资产重组。同时，根据《深圳证券交易所创业板股票上市 规则》的相关规定，本次交易构成关联交易。为本次交易之目的，公司聘请 了中联资产评估咨询（上海）有限公司（以下简称"中联评估"）作为本次交 易的评估机构。 公司董事会就评估机构独立性、评估假设前提合理性、评估方法与评估目 的相关性及交易定价公允性进行了审慎分析，具体如下： 一、评估机构的独立性 公司聘请中联资产评估作为本次交易的评估机构，承担本次交易的评估工 作。中联评估具有法定评估资格，中联评估及其经办评估师与公司、交易对方、 标的公司之间除本次交易正常业务往来之外，不存在其他关联关系，也不存在 除专业收费外的现实或可预期的利益关系或冲突，评估机构具有独立性。 二、评估假设前提的合理性 评估机构和评估人员所设定的评估假设前提和限制条件按照国家有关法规 和规定执行、遵循了市场通 ...

关于收购控股子公司少数股东股权的议案》，同意公司以自有资金人民币 （有限合伙）、兴化几何管理咨询有限公司合计持有的南京万好商业管理有 限公司（以下简称"南京万好"）49%的股权。公司于2024年8月19日办理 完成相关工商变更登记手续。南京万好主要从事休闲食品为主的采购、销售 及运营业务，与本次交易标的公司的主营业务属于相同或相近业务范围，因 此计算本次交易构成重大资产重组时应纳入累计计算的范围。 除上述交易外，公司在审议本次交易方案的董事会召开日前十二个月内 不存在其他购买、出售资产与本次交易购买的标的资产属于同一或相关资产 的情况。 特此说明。 （以下无正文） （本页无正文，为《福建万辰生物科技集团股份有限公司董事会关于本 次交易前十二个月内购买、出售资产情况的说明》之盖章页） 福建万辰生物科技集团股份有限公司董事会 福建万辰生物科技集团股份有限公司董事会 关于本次交易前十二个月内购买、出售资产情况的说明 福建万辰生物科技集团股份有限公司（以下简称"公司"）拟以支付现 金的方式购买淮南市盛裕企业管理有限公司和淮南市会想企业管理有限公司 合计持有的南京万优商业管理有限公司（以下简称"标的公司"）49.00% ...

Core Viewpoint - The company plans to acquire a 49% stake in Nanjing Wanyou Commercial Management Co., Ltd. through cash payment, which constitutes a major asset restructuring and related party transaction [1] Group 1: Financial Impact of the Transaction - The company's net profit before the transaction is 358.58 million yuan, projected to increase to 415.52 million yuan after the transaction [1] - Basic earnings per share (EPS) will rise from 1.99 yuan to 2.31 yuan post-transaction [1] Group 2: Measures to Mitigate Dilution of Immediate Returns - The company aims to enhance the biological conversion rate of edible mushrooms by optimizing cultivation processes and improving breeding formulas [2] - Focus will remain on the high-quality development of the bulk snack business, leveraging brand influence to improve operational efficiency and profitability [2] - The company will adhere to legal and regulatory requirements to optimize governance structures and strengthen internal controls, ensuring the protection of minority shareholders' rights [2] Group 3: Commitment from Major Stakeholders - The controlling shareholder and actual controller commit to not interfering in the company's management and to protect the company's interests [4] - Company directors and senior management pledge to diligently fulfill their responsibilities and ensure the execution of return compensation measures is linked to their remuneration [4]

Core Viewpoint - The company plans to acquire a 49.00% stake in Nanjing Wanyou Commercial Management Co., Ltd. from Huainan Shengyu Enterprise Management Co., Ltd. and Huainan Huixiang Enterprise Management Co., Ltd. through a cash payment, which constitutes a major asset restructuring and related party transaction [1][2]. Group 1 - The transaction aims to strengthen the company's control over its subsidiary, enhance overall governance, and align with the company's long-term development strategy, thereby improving its competitive edge [2]. - The target company's main business is retail snack sales, which aligns with the company's primary business of retail snack sales and the research, cultivation, and sales of edible fungi, both classified under "F52 Retail" in the national economic industry classification [2]. - The transaction complies with the relevant provisions of the "Continuous Supervision Measures for GEM Listed Companies (Trial)" and the "Major Asset Restructuring Review Rules of the Shenzhen Stock Exchange" [1][2].

福建万辰生物科技集团股份有限公司（以下简称 "上市公司"或"公 司"）拟以支付现金的方式购买淮南市盛裕企业管理有限公司和淮南市会想 企业管理有限公司合计持有的南京万优商业管理有限公司49.00%股权（以下 简称"本次交易"）。根据《上市公司重大资产重组管理办法》相关规定， 本次交易构成重大资产重组。同时，根据《深圳证券交易所创业板股票上市 规则》的相关规定，本次交易构成关联交易。 福建万辰生物科技集团股份有限公司董事会 关于本次交易相关主体不存在《上市公司监管指引第 7 号—— 上市公司重大资产重组相关股票异常交易监管》 第十二条情形的说明 福建万辰生物科技集团股份有限公司董事会 特此说明。 （以下无正文） （本页无正文，为《福建万辰生物科技集团股份有限公司董事会关于本 次交易相关主体不存在 <上市公司监管指引第7号 上市公司重大资产重组="上市公司重大资产重组"> 相关股票异常交易监管>第十二条情形的说明》之盖章页） 根据中国证券监督管理委员会（以下简称"中国证监会"）《上市公司 监管指引第 7 号——上市公司重大资产重组相关股票异常交易监管》第十二 条的规定，上市公司董事会就本次交易相关主体是否存在不得参 ...